Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study.
Saved in:
| Title: | Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study. |
|---|---|
| Authors: | Isfort S; Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany. sisfort@ukaachen.de.; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen Bonn Cologne Düsseldorf, Germany. sisfort@ukaachen.de., Manz K; Institute for Medical Information Processing, Biometry and Epidemiology (IBE), Faculty of Medicine, LMU Munich, Munich, Germany.; Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany., Teichmann LL; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen Bonn Cologne Düsseldorf, Germany.; Department of Medicine III, University Hospital Bonn, Bonn, Germany., Crysandt M; Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany.; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen Bonn Cologne Düsseldorf, Germany., Burchert A; Dep. of Internal Medicine, Hematology, Oncology and Immunology, Philips Univ. Marburg, Marburg, Germany., Hochhaus A; Hematology/Oncology, Universitätsklinikum Jena, Jena, Germany., Saussele S; Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg, Germany., Kiani A; Department of Oncology and Hematology, Klinikum Bayreuth, Bayreuth, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany., Göthert JR; Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Illmer T; Hematology-Oncology Practice, Dresden, Germany., Schafhausen P; Department of Oncology, Hematology and Bone Marrow Transplantation With Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Al-Ali HK; University Hospital Halle, Halle (Saale), Germany., Stegelmann F; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Hänel M; Department of Internal Medicine III, Küchwald Hospital Chemnitz, Chemnitz, Germany., Pfeiffer T; Department of Hematology and Oncology, Klinikum Augsburg, Augsburg, Germany., Giagounidis A; Clinic for Oncology, Hematology, and Palliative Medicine, Marien Hospital Düsseldorf, Düsseldorf, Germany., Franke GN; Medical Clinic I, University Hospital of Leipzig, Leipzig, Germany., Koschmieder S; Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany.; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen Bonn Cologne Düsseldorf, Germany., Fabarius A; Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg, Germany., Ernst T; Hematology/Oncology, Universitätsklinikum Jena, Jena, Germany., Warnken-Uhlich M; Clinical Study Core Unit Bonn, Institute of Clinical Chemistry and Clinical Pharmacology, University Bonn, Bonn, Germany., Wolber U; Clinical Study Core Unit Bonn, Institute of Clinical Chemistry and Clinical Pharmacology, University Bonn, Bonn, Germany., Kohn D; Institute for Medical Information Processing, Biometry and Epidemiology (IBE), Faculty of Medicine, LMU Munich, Munich, Germany., Pfirrmann M; Institute for Medical Information Processing, Biometry and Epidemiology (IBE), Faculty of Medicine, LMU Munich, Munich, Germany., Wolf D; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen Bonn Cologne Düsseldorf, Germany.; Department of Medicine III, University Hospital Bonn, Bonn, Germany.; Internal Medicine V, Department for Hematology and Oncology, Comprehensive Cancer Center Innsbruck (CCCI), Tyrolean Cancer Research Institute (TKFI), Medical University of Innsbruck (MUI), Innsbruck, Austria., Brümmendorf TH; Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany.; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen Bonn Cologne Düsseldorf, Germany. |
| Corporate Authors: | German CML study group |
| Source: | Annals of hematology [Ann Hematol] 2023 Oct; Vol. 102 (10), pp. 2741-2752. Date of Electronic Publication: 2023 Aug 18. |
| Publication Type: | Clinical Trial, Phase II; Multicenter Study; Journal Article |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1432-0584 |
|---|---|
| DOI: | 10.1007/s00277-023-05394-0 |
